Want to see IN:JHS full AI Analyst Report?
JHS Stock Chart & Stats
₹7.41
-₹0.09(-1.20%)
At close: 4:00 PM EDT
₹7.41
-₹0.09(-1.20%)
Day’s Range― - ―
52-Week Range₹6.15 - ₹13.83
Previous CloseN/A
Volume57.65K
Average Volume (3M)15.39K
Market Cap
₹713.23M
Enterprise Value₹858.31
Total Cash (Recent Filing)₹191.00M
Total Debt (Recent Filing)₹148.51M
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Nov 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding87,405,770
10 Day Avg. Volume10,816
30 Day Avg. Volume15,389
Financial Highlights & Ratios
PEG Ratio0.33
Price to Book (P/B)0.33
Price to Sales (P/S)0.56
P/FCF Ratio-3.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage limits solvency pressure and interest burden, giving JHS greater financial flexibility to manage operating volatility and invest in production capacity without relying heavily on additional borrowing.
Revenue RecoveryThe FY2026 recovery indicates that demand and operating activity improved after a volatile period. A return to positive EBITDA provides a base for further margin repair if volumes and production efficiency continue improving.
Consumer Goods Manufacturing ExposureContract and third-party manufacturing can provide recurring volume opportunities through established consumer brands, while oral and personal care products serve ongoing household-use categories rather than discretionary one-time purchases.
Bears Say
Persistent LossesContinued net and operating losses show that the business has not yet converted revenue into sustainable shareholder returns. This limits internal funding capacity and leaves profitability dependent on meaningful margin and cost improvements.
Weak Cash GenerationRecurring operating and free-cash-flow deficits increase execution risk even with low debt. If cash burn persists, JHS may need working-capital support or external funding, reducing flexibility to sustain growth and absorb setbacks.
Margin CompressionSharp gross-margin deterioration suggests pricing pressure, higher input costs, or an unfavorable product mix. Unless the company restores pricing power or manufacturing efficiency, revenue growth may not translate into durable earnings improvement.
JHS Svendgaard Laboratories Limited News
JHS FAQ
What was JHS Svendgaard Laboratories Limited’s price range in the past 12 months?
JHS Svendgaard Laboratories Limited lowest stock price was ₹6.15 and its highest was ₹13.83 in the past 12 months.
What is JHS Svendgaard Laboratories Limited’s market cap?
JHS Svendgaard Laboratories Limited’s market cap is ₹713.23M.
When is JHS Svendgaard Laboratories Limited’s upcoming earnings report date?
JHS Svendgaard Laboratories Limited’s upcoming earnings report date is Nov 11, 2026 which is in 69 days.
How were JHS Svendgaard Laboratories Limited’s earnings last quarter?
JHS Svendgaard Laboratories Limited released its earnings results on Aug 11, 2026. The company reported ₹0.127 earnings per share for the quarter.
Is JHS Svendgaard Laboratories Limited overvalued?
According to Wall Street analysts JHS Svendgaard Laboratories Limited’s price is currently Overvalued.
Does JHS Svendgaard Laboratories Limited pay dividends?
JHS Svendgaard Laboratories Limited pays a Annually dividend of ₹3.64 which represents an annual dividend yield of N/A. See more information on JHS Svendgaard Laboratories Limited dividends here
What is JHS Svendgaard Laboratories Limited’s EPS estimate?
JHS Svendgaard Laboratories Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does JHS Svendgaard Laboratories Limited have?
JHS Svendgaard Laboratories Limited has 87,405,770 shares outstanding.
What happened to JHS Svendgaard Laboratories Limited’s price movement after its last earnings report?
JHS Svendgaard Laboratories Limited reported an EPS of ₹0.127 in its last earnings report. Following the earnings report the stock price went up 14.591%.
Which hedge fund is a major shareholder of JHS Svendgaard Laboratories Limited?
Currently, no hedge funds are holding shares in IN:JHS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
JHS Svendgaard Laboratories Limited
JHS Svendgaard Laboratories Limited, along with its associated companies, specializes in the manufacturing and sale of a diverse array of oral and dental hygiene products, catering to both adults and children throughout India. Their extensive product range includes essential oral care items such as toothbrushes, toothpastes, and mouthwashes, predominantly marketed under the Dr. Gold and Aquawhite brand names. The company also produces other personal and household goods, including hand sanitizers, laundry detergents, room fresheners, and denture care solutions. Beyond its own brands, JHS Svendgaard Laboratories provides contract manufacturing services for oral care products to other companies and operates retail outlets within various airports. The firm also engages in international trade, exporting its goods to global markets. Established in 1996, the company's base of operations is situated in New Delhi, India.
Technical Analysis
Colgate-Palmolive (India) Limited
―
Dabur India Limited
―
Emami Limited
―
Godrej Consumer Products Limited
―
Honasa Consumer Limited
―